These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 37606429

  • 1. Review of the Case Reports on Metformin, Sulfonylurea, and Thiazolidinedione Therapies in Type 2 Diabetes Mellitus Patients.
    Susilawati E, Levita J, Susilawati Y, Sumiwi SA.
    Med Sci (Basel); 2023 Aug 15; 11(3):. PubMed ID: 37606429
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.
    Asche CV, McAdam-Marx C, Shane-McWhorter L, Sheng X, Plauschinat CA.
    Drugs Aging; 2008 Aug 15; 25(7):611-22. PubMed ID: 18582148
    [Abstract] [Full Text] [Related]

  • 3. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ, Bailey CJ.
    Drugs; 2005 Aug 15; 65(3):385-411. PubMed ID: 15669880
    [Abstract] [Full Text] [Related]

  • 4. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy.
    Hollander P, Sugimoto D, Vlajnic A, Kilo C.
    J Diabetes Complications; 2015 Aug 15; 29(8):1266-71. PubMed ID: 26281972
    [Abstract] [Full Text] [Related]

  • 5. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH, Man KKC, Shi M, Chan EW, Ho CW, Tse ETY, Wong ICK, Lam CLK.
    PLoS Med; 2019 Dec 15; 16(12):e1002999. PubMed ID: 31877127
    [Abstract] [Full Text] [Related]

  • 6. Effects of thiazolidinediones and sulfonylureas in patients with diabetes.
    Derosa G, Maffioli P.
    Diabetes Technol Ther; 2010 Jun 15; 12(6):491-501. PubMed ID: 20470234
    [Abstract] [Full Text] [Related]

  • 7. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
    Dennis JM, Henley WE, Weedon MN, Lonergan M, Rodgers LR, Jones AG, Hamilton WT, Sattar N, Janmohamed S, Holman RR, Pearson ER, Shields BM, Hattersley AT, MASTERMIND Consortium.
    Diabetes Care; 2018 Sep 15; 41(9):1844-1853. PubMed ID: 30072404
    [Abstract] [Full Text] [Related]

  • 8. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP, McMahon GT.
    Mt Sinai J Med; 2009 Jun 15; 76(3):234-43. PubMed ID: 19421967
    [Abstract] [Full Text] [Related]

  • 9. Oral antihyperglycemic treatment options for type 2 diabetes mellitus.
    Brietzke SA.
    Med Clin North Am; 2015 Jan 15; 99(1):87-106. PubMed ID: 25456645
    [Abstract] [Full Text] [Related]

  • 10. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
    Dubois M, Vantyghem MC, Schoonjans K, Pattou F.
    Ann Endocrinol (Paris); 2002 Dec 15; 63(6 Pt 1):511-23. PubMed ID: 12527853
    [Abstract] [Full Text] [Related]

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Dec 15; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 12. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
    Aquilante CL, Zhang W, McCollum M.
    Curr Med Res Opin; 2007 Mar 15; 23(3):489-94. PubMed ID: 17355730
    [Abstract] [Full Text] [Related]

  • 13. Assessment of the relative effectiveness and tolerability of treatments of type 2 diabetes mellitus: a network meta-analysis.
    Zintzaras E, Miligkos M, Ziakas P, Balk EM, Mademtzoglou D, Doxani C, Mprotsis T, Gowri R, Xanthopoulou P, Mpoulimari I, Kokkali C, Dimoulou G, Rodopolou P, Stefanidis I, Kent DM, Hadjigeorgiou GM.
    Clin Ther; 2014 Oct 01; 36(10):1443-53.e9. PubMed ID: 25109773
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
    Derosa G.
    Drugs; 2010 Oct 22; 70(15):1945-61. PubMed ID: 20883052
    [Abstract] [Full Text] [Related]

  • 15. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.
    Seufert J, Lübben G, Dietrich K, Bates PC.
    Clin Ther; 2004 Jun 22; 26(6):805-18. PubMed ID: 15262452
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Progress with thiazolidinediones in the management of type 2 diabetes mellitus.
    Meriden T.
    Clin Ther; 2004 Feb 22; 26(2):177-90. PubMed ID: 15038941
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Complementing insulin therapy to achieve glycemic control.
    Barnett AH.
    Adv Ther; 2013 Jun 22; 30(6):557-76. PubMed ID: 23797471
    [Abstract] [Full Text] [Related]

  • 20. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
    Setter SM, Iltz JL, Thams J, Campbell RK.
    Clin Ther; 2003 Dec 22; 25(12):2991-3026. PubMed ID: 14749143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.